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Background: The importance of the hippocampus and amygdala for disrupted emotional memory formation in depression is 20 
well-recognized, but it remains unclear whether functional abnormalities are state-dependent and whether they are affected by 21 
persistence of depressive symptoms. 22 
Methods: Thirty-nine patients with major depressive disorder (MDD) and twenty-eight healthy controls (HC) were included from 23 
the longitudinal functional magnetic resonance imaging (fMRI) sub-study of the Netherlands Study of Depression and Anxiety. 24 
Participants performed an emotional word-encoding and -recognition task during fMRI at baseline and two-year follow-up 25 
measurement. At baseline, all patients were in a depressed state. We investigated state-dependency by relating changes in 26 
brain activation over time to changes in symptom severity. Furthermore, effect of time spent with depressive symptoms in the 27 
two-year interval was investigated.  28 
Results: Symptom change was linearly associated with higher activation over time of the left anterior hippocampus extending to 29 
the amygdala during positive and negative word-encoding. Especially during positive word encoding, this effect was driven by 30 
symptomatic improvement. There was no effect of time spent with depression in the two-year interval on change in brain 31 
activation. Results were independent of medication- and psychotherapy-use.  32 
Conclusion: Using a longitudinal within-subjects design we showed that hippocampal-amygdalar activation during emotional 33 
memory formation is related to depressive symptom severity but not persistence (i.e. time spent with depression or ‘load’), 34 
suggesting functional activation patterns in depression are not subject to functional ‘scarring’ although this hypothesis 35 
awaits future replication. 36 
37 
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Major depressive disorder (MDD) is a prevalent psychiatric disorder associated with high morbidity and mortality, frequently 39 
characterized by a chronic or recurrent course (Kessler et al 2005). Biased emotional memory has been proposed as a key 40 
factor for the development and maintenance of MDD (Ai et al 2015, Disner et al 2011, Everaert et al 2015, Leppänen 2006) and 41 
may even underlie the vulnerability for depressive psychopathology (Chan et al 2007). Cross-sectional studies suggested that 42 
emotional memory biases are state-independent phenomena: better memory for negative information and worse memory for 43 
positive information have been reported during both the acute depressive state and during remission (reviewed elsewhere 44 
(Bradley and Mathews 1988, Elliott et al 2010)), mirroring functional brain abnormalities observed in areas critical for memory 45 
formation of emotional material, i.e. the amygdala and hippocampus (Arnold et al 2011, Ramel et al 2007, van Tol et al 2012). 46 
Previously, we however observed hyperactivation of the anterior hippocampus/amygdala during encoding of negative 47 
information in acutely depressed patients but not in remitted patients in a cross-sectional comparison (van Tol et al 2012), 48 
suggesting state-dependency instead. However, cross-sectional studies do not allow strong inferences on state-dependency. 49 
Importantly, identifying state-dependent neurocognitive markers of MDD may constitute a first step in understanding 50 
mechanisms of recovery versus maintenance of depression (Dohm et al 2017, Maalouf et al 2012, Mayberg 1997).  51 
While longitudinal neuropsychological studies have found that memory biases resolve upon recovery after treatment (Calev 52 
et al 1986, Peselow et al 1991) (though not consistently in Sternberg and Jarvik 1976), functional neuroimaging studies reported 53 
mostly changes in activation of the amygdala and hippocampus following symptomatic improvement during affective processing 54 
(i.e., not in the context of memory processing) or rest. Findings have been inconclusive with reports of decreased (Fu et al 2004, 55 
Sheline et al 2001, Redlich et al 2017), increased (Goldapple et al 2004, Neumeister et al 2006, Ritchey et al 2011, Victor et al 56 
2010), or unchanged (Fu et al 2015, Opmeer et al 2015) activation following successful short-term pharmacological treatment 57 
(Fu et al 2004, Sheline et al 2001, Victor et al 2010,,Fu et al 2015), electroconvulsive therapy (Redlich et al 2017), cognitive 58 
behavioral treatment (Fu et al 2008, Goldapple et al 2004, Ritchey et al 2011), or naturalistic remission (Opmeer et al 2015). 59 
Heterogeneity in findings may be partly explained by methodological factors such as small sample size, type of stimuli, effects of 60 
the (pharmacological) treatment itself on blood flow, or clinical variation in terms of comorbidity or interval between pre- and 61 
post-measurement. Nevertheless, the effects of symptomatic improvement on the neural underpinnings of emotional memory 62 
processing have not been studied to date. 63 
Because duration of depression has been associated with more severe structural abnormalities, especially in the 64 
hippocampus (Frodl et al 2008, MacQueen et al 2003, Schmaal et al 2015), persistence of depressive symptoms may be an 65 
important additional factor that influences activation of brain areas important for encoding of emotional information. Such 66 
‘persistence’ effects may be related to glucocorticoid-dependent toxic effects of stress (Fossati et al 2004) and may result in 67 
explicit memory deficits (Sapolsky 2000). On a functional level, medial prefrontal involvement during processing of 68 
autobiographical memory was found to be blunted in remitted MDD patients but not in individuals at high-risk for developing 69 
MDD (Young et al 2015), suggesting that memory deficits may be a consequence of having experienced a depressive episode. 70 
However, to our knowledge, it has not yet been investigated whether persistence of symptoms may modulate longitudinal 71 
functional brain changes related to memory formation.  72 
In the present longitudinal imaging study, we aimed to investigate whether changes in activation of the amygdala and 73 
hippocampus during emotional memory encoding are dependent on changes in depressive state and time spent with depressive 74 
symptoms. Healthy and depressed participants underwent functional magnetic resonance imaging (fMRI) twice in the context of 75 
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the naturalistic and observational Netherlands Study of Depression and Anxiety (NESDA) study, with approximately two years in 76 
between. In this interval, no specific treatment was delivered as part of the study protocol. Given the naturalistic design 77 
of our study, participants could receive treatment as usual, which was reconstructed retrospectively based on self-78 
reports at the two-year follow-up interview. We hypothesized that changes in activation in the hippocampus/amygdala are 1) 79 
associated with change in depressive state, especially during negative word encoding and 2) affected by time spent with 80 
depressive symptoms between measurements. Furthermore, we aimed to explore whether activation in regions other than 81 
amygdala and hippocampus related to longitudinal treatment responses was associated with severity and time spent with 82 
depressive symptoms.  83 
84 
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Methods and materials 85 
Participants  86 
Participants were recruited from the ongoing neuroimaging sub-study of the Netherlands Study of Depression and Anxiety 87 
(NESDA)(Penninx et al 2008) and underwent fMRI scanning at the University Medical Center Groningen (UMCG), Academic 88 
Medical Center (AMC) of the University of Amsterdam, and the Leiden University Medical Center (LUMC). NESDA has been 89 
designed as a longitudinal observational cohort study with measurements at baseline, one-, two-, four-, six-, and nine-year 90 
follow-up, with MRI-measurements performed in a subsample at baseline, two- and nine-year follow up (nine-year follow-up 91 
measurement was completed during the preparation of this manuscript). At baseline, patients with MDD (n=70), MDD and one 92 
or more anxiety disorders (i.e. social anxiety disorder (SAD), panic disorder (PD) and/or generalized anxiety disorder (GAD); 93 
N=92), patients with only anxiety disorders (i.e. SAD, PD, and/or GAD; n=71), and healthy control participants (HC; n=68) were 94 
included. The ethical review board of each participating center approved the study and all participants gave written informed 95 
consent.  96 
Exclusion criteria for all participants in the NESDA neuroimaging study at baseline (n=301) were: age under 18 or over 97 
57 years; current alcohol or substance abuse; presence or history of a neurological or somatic disorder with possible effects on 98 
the central nervous system; general 3T MRI contraindications; hypertension. Use of selective serotonin reuptake inhibitors 99 
(SSRIs) or infrequent use of benzodiazepines (oxazepam [max 20 mg] or diazepam, maximum of three times a week and not 100 
within 48 hours before scanning) was allowed. Patients using any other psychopharmacological agent were excluded. Exclusion 101 
criteria for the second measurement at two-year follow-up (S2; N=199) were identical, with the exception of the age criterion. 102 
Also, from a cohort perspective, we were less strict in excluding patients based on type of medication used at S2 (see Table 1 103 
and Supplementary Table S1 for details). In line with the observational nature of the NESDA study, no specific treatment was 104 
delivered in between measurements, but was monitored retrospectively. Participants were free to consult their general 105 
practitioner, psychiatrist or psychologist for the help they wished to receive.  Results of the baseline measurement (S1) and their 106 
associations with subsequent course related to emotional memory processing have been published elsewhere (Ai et al 2015, 107 
van Tol et al 2012). 108 
Complete behavioral data and good quality fMRI data at both S1 and S2 were available of 64 MDD patients and 39 109 
HC. At S1, all patients fulfilled the criteria for a diagnosis of MDD with a half-year recency based on the Composite International 110 
Diagnostic Interview (CIDI life time - version 2). An additional diagnosis of SAD, PD and/or GAD at either S1 or S2 was allowed 111 
(See Table 1 for details). Following Opmeer et al., (Opmeer et al 2015), we included only patients who were in a depressive 112 
state at S1 defined as a Montgomery–Åsberg Depression Rating Scale (MADRS) score larger than 10 (Zimmerman et al 2004). 113 
One participant had a huge increase in MADRS score at S2 and was classified as an outlier (change score >3SD from group 114 
mean) and subsequently excluded from the analyses. The final patient sample included 39 individuals. In total, 11 HC were 115 
excluded from further analysis based on the presence of possible depressive symptomatology at S2 (i.e. MADRS-score >10; 116 
n=1), too high level of education to be matched to the patient group (n=1) or unreliable task performance (n=9; Supplementary 117 
Figure S1). This resulted in the inclusion of 28 HC without any current or life-time DSM-IV diagnosis and no indication of 118 
depressive symptomatology at both S1 and S2 (See Supplementary Figure S1 for a flow diagram reflecting data selection).  119 
 120 
Task paradigm 121 
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All participants performed the event-related, subject-paced, emotional word encoding and recognition task during both fMRI 122 
scanning sessions (S1 and S2)(van Tol et al 2012). During the encoding phase, 20 blocks containing 160 stimuli (positive/ 123 
neutral/ negative words and baseline trials; 40 each) were pseudo-randomly presented. Participants were instructed to evaluate 124 
whether the word was positive, negative or neutral in valence by pressing the right, left and middle button, respectively. During 125 
baseline trials, participants were asked to press the corresponding button to indicate the direction of the arrow. After a retention 126 
interval of 10 minutes (during which the structural T1 scan was acquired), the retrieval phase started and consisted of 120 127 
encoding target words, 120 distracter words and 40 baseline words that were presented in 20 pseudo-randomized blocks. 128 
Participants were instructed to indicate whether they had seen, had not seen, or probably had seen the word. Emotional words 129 
in the valence categories were matched based on length, frequency in the Dutch language and complexity. The same words list 130 
was used in both measurements, although the order was changed at the two-year follow-up measurement. The emotional word 131 
encoding task was preceded by an executive planning task (van Tol et al 2011) and followed by an emotional face viewing task 132 
(Demenescu et al 2011, Opmeer et al 2015) and a resting state acquisition (Veer et al 2010). Based on the hypotheses 133 
formulated in our cross-sectional study (van Tol et al 2012), we only investigated the encoding session. 134 
 135 
fMRI data acquisition 136 
Neuroimaging data were collected with 3T Philips MR-scanners located in Amsterdam, Leiden, and Groningen using standard 137 
EPI techniques, though with minor differences in acquisition parameters. A detailed description of acquisition specifications can 138 
be found in the supplemental material.  139 
 140 
Data analysis 141 
Independent variables 142 
Firstly, to test for the correlation between symptom change and brain activation change over time, a relative symptom change 143 
score representing the difference in depression severity between S1 and S2 while taking into account baseline severity was 144 
calculated for each patient (i.e., [MADRS S2 – MADRS S1]/MADRS S1). Furthermore, to be able to compare changes over time 145 
in behavior and brain activation following symptomatic change with changes in HC, who were also scanned twice, and to 146 
explore e.g. whether change in the high improved patients represented normalization (i.e., approached activation of HC at S2) 147 
or whether change in low improved patients represented further deviations from normal, we divided the patients in two groups 148 
based on the median of relative symptom change scores (median = -.46): a group of high improved (MDD-HI; n=20, 149 
Supplementary Figure S1) and a group of low improved patients (MDD-LI; n=19).  150 
Secondly, to test for the correlation between brain activation change and percentage of time spent with depression (i.e. 151 
persistence), presence of depressive symptoms per month for the duration of the interval between S1 and S2 was assessed 152 
with the life chart interview (Lyketsos et al 1994) at S2. Participants had to rate the severity of depressive symptoms per month 153 
and only symptoms with small to severe burden were taken as indication of presence of symptoms. Percentage of months 154 
experiencing depressive symptoms relative to the overall follow-up period was calculated per patient as time spent with 155 
depression (Ai et al 2015). 156 
 157 
Clinical variables and behavioral data 158 
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Effects of symptom change and time spent with depressive symptoms on demographic, psychometric assessment and memory 159 
performance were analyzed in IBM SPSS software (SPSS v.22.0, IBM). We employed analyses of covariance (ANCOVA), Chi-160 
square tests and t-tests where appropriate for demographic and psychometric data with a significance level of p<.05, two-tailed.  161 
For the behavioral data, performance difference scores (S2-S1) for both reaction times (RT) and accuracy for 162 
successfully encoded words (Tulving 1985) were calculated. We assessed the continuous association between relative 163 
symptom change scores and depressive duration, and RT and accuracy difference scores over time in patients. Age and years 164 
of education were included as covariates. A sensitivity analysis was performed within patients who showed symptomatic 165 
improvement (thus, patients who were equally or more depressed at S2 than at S1 were excluded; n=6). 166 
Additionally, to investigate whether patients (MDD-HI/LI) performed differently over time as compared to HC, we set 167 
up a group (3; HC, HI, LI) × valence (3; positive, negative, neutral) × time (2; S1, S2) repeated measures ANCOVA, with age 168 
and years of education as covariates. Effects were considered significance at p<.05. Where appropriate, Bonferroni correction 169 
for multiple comparisons was applied. 170 
 171 
Imaging data preprocessing  172 
For the fMRI data, preprocessing and task modeling was performed with Statistical Parametric Mapping software (SPM8, 173 
Wellcome Trust Center for Neuroimaging, http://www.fil.ion.ucl.ac.uk/spm) implemented in Matlab 7.8 (The Math Works Inc., 174 
Natick, MA, USA). A detailed description of the preprocessing steps and first-level modeling can be found in the supplemental 175 
material.  176 
 177 
Effects of change of depressive state  178 
To test for the association between symptom change and change of brain activation during positive and negative encoding over 179 
the two-year interval, scan moments, S2-S1 contrast maps were entered as dependent variables in a full-factorial model, with 180 
valence (successfully encoded positive words>successfully encoded neutral words [S2-S1], successfully encoded 181 
negative words>successfully encoded neutral words [S2-S1]) as interacting factor with valence. Contrast maps were built 182 
for successful encoding of positive words (vs. successful encoding of neutral words) and negative words separately. 183 
To control for the possible confounding effects of variations within and between participants in scanning site (which coincided 184 
with minor variations in sequence and coil; see supplementary material), four dummy variables for site (i.e., both times scanned 185 
in AMC; changed from AMC to LUMC; changed from LUMC to AMC; both times scanned in UMCG; both times scanned in 186 
LUMC) were defined as covariates of no interest. In addition, age and years of education at S1 were added as covariates.  187 
We repeated our analysis with the following possible confounding factors added separately to the model: percentage 188 
of time spent with depression, relative changes in anxiety severity assessed by Beck Anxiety Inventory ([BAI-scores S2-S1]/ 189 
BAI-scores S1) (Beck et al 1988), SSRI-use, and participation in psychotherapy. SSRI-use at/between S1 and S2 was added to 190 
the model by means of three dummy variables (used at both S1 and S2, started after S1, stopped after S1, both not used). 191 
Psychotherapy-use between S1 and S2 was coded as a dummy variable and added as covariate to test for the effect of 192 
psychotherapy. Use of SSRI and psychotherapy between S1 and S2 are summarized in Supplementary Table S1.  193 
A sensitivity analysis was planned to test whether associations would hold in the analysis including only patients 194 
with symptomatic improvement (n=33). 195 
 196 
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Effects of persistence of depressive symptoms 197 
We built a full factorial model with valence as factor (2; successfully encoded positive words>successfully encoded 198 
neutral words and successfully encoded negative words>successfully encoded neutral words) and time spent with 199 
depressive symptoms as an interacting covariate with valence. Site (four dummy variables), age, and years of education were 200 
added as covariates. We tested for the effects of time spent with depressive symptoms during encoding of positive words and 201 
negative words separately. In a subsequent step, relative symptom change of depressive and anxiety symptom severity and 202 
treatment at S1 and S2 (medication-and psychotherapy use; yes/no) were added separately as covariates to statistically control 203 
for their possible confounding effects. 204 
A sensitivity analysis was planned within patients with symptomatic improvement. 205 
 206 
Statistical thresholding 207 
Based on previous studies (see introduction), we a priori defined the bilateral hippocampus and amygdala as our regions-of-208 
interest (ROI) and built one composite mask encompassing these regions. The regions were defined according to the 209 
automated anatomical labels of the Wake Forest University (WFU, Winston Salem, North Carolina) Pick Atlas toolbox. Small 210 
volume correction for multiple comparisons was applied within the ROI. F-tests in the main and follow-up analyses were 211 
explored separately for positive and negative words at p<.001 uncorrected. Post hoc t-tests were regarded significant at a 212 
threshold of p<.05 family wise error (FWE) corrected at voxel-level (with an initial threshold of p<.001 uncorrected). We also 213 
examined the effects in other brain regions than ROIs, which had to meet p<.05, FWE whole-brain corrected to be 214 
considered significant. 215 
216 
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Demographic characteristics 218 
Demographics and clinical characteristics of all patients and healthy controls are summarized in Table 1 and supplementary 219 
material. Clinical characteristics of high-improved and low-improved patient groups that were included in explorative post-hoc 220 
analyses are listed in Supplementary Table and Supplementary results. Thirty-three patients showed symptomatic improvement 221 
(S2<S1), two remained stable (S2=S1) and four showed more severe symptoms at S2 (S2>S1). 222 
 223 
Behavioral results 224 
No correlations were found between relative depressive symptom change and changes in performance on memory of positive, 225 
neutral or negative words over time (i.e., RTs and accuracy) (p>.05). Sensitivity analyses within symptomatically improved 226 
patients only (n=33) did not change this result. Group × Time repeated measures ANOVA indicated no changes neither in 227 
performance and response times in HC nor a difference between HC and HI or LI (ps>.05).  228 
There was no association between time spent with depressive symptoms and changes in behavioral performance 229 
(p>.05). 230 
 231 
fMRI results 232 
Correlations with change of depressive state  233 
Relative symptom change was negatively correlated with activation change in the bilateral hippocampal/amygdala during both 234 
positive and negative word encoding (Table 2; Figure 1). However, only the effect in the left hippocampus survived multiple 235 
comparison correction and indicated that larger symptomatic improvement coincided with a larger increase in left anterior 236 
hippocampal activation during encoding of emotional information.  237 
Adding time spent with depressive symptoms in the interval between S1 and S2 as covariate did not change the 238 
results (Z=3.85, pFWE=.019 for successfully encoded positive words>successfully encoded neutral words (pos); Z=3.95, 239 
pFWE=.014 for successfully encoded negative words>successfully encoded neutral words (neg)). Also, results were not 240 
affected by including change in anxiety severity as a covariate to the model (pos: Z=3.82, pFWE =.021; neg: Z=3.77, pFWE =.025) 241 
or by adding SSRI-use at S1 and S2 as covariates (pos: Z=3.68, pFWE =.034; neg: Z=3.49, pFWE =.06). Results bordered 242 
statistical significance after adding psychotherapy as a covariate (pos: Z=3.59, pFWE =.05; neg: Z=3.54, pFWE =.05).  243 
When repeating the analysis in the symptomatically improved patients only, the negative correlation between 244 
symptom change and brain activation change in the hippocampus was observed subthreshold (MNI coordinates:[x=-18, y=-13, 245 
z=-11], Z=3.51, pFWE=.09) during positive encoding, and was not significant during negative encoding (pFWE=.50). 246 
Furthermore, post hoc group comparison (detailed in the supplementary methods and results) showed that activation 247 
estimates in our main cluster did not change in HC over time, and plots suggested a trend of normalization during positive but 248 
not negative word encoding in the high-improved group (Supplementary Figure 3A&3B). 249 
 250 
Correlations with time spent with depressive symptoms and course 251 
No correlation between percentage of time with depressive symptoms and changes in brain activation was observed across all 252 
MDD patients during successful encoding on positive and negative words. Adding change in depressive and anxiety 253 
symptoms or medication/therapy use to the model did not change this observation.  254 
255 
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In this longitudinal study, we examined changes in emotion-related brain activation over time associated with symptomatic 257 
improvement and time spent with depressive symptoms in depressed patients. Symptomatic improvement was associated with 258 
increased responses in the anterior hippocampus/amygdala during encoding of emotional stimuli over time. Follow-up 259 
explorations indicated that increased activation of the hippocampal/amygdala responsiveness occurred in the direction of 260 
normalization, especially for the encoding of positive words. The effect was unrelated to changes in anxiety severity, and use of 261 
SSRIs, although it became smaller after adding use of psychotherapy as a covariate. No relation was observed between 262 
depression duration (i.e. time spent with depressive symptoms) in the two-year follow-up nor were changes in hippocampal and 263 
amygdalar activation observed. These results suggest that hippocampal activation during emotional memory formation changes 264 
with symptomatic improvement, but is not subject to functional ‘scarring’ as a result of enduring symptom manifestation. Our 265 
results indicate that symptomatic improvement is at least partially associated with normalization of limbic responsiveness to 266 
positive material.  267 
Based on previous reports on memory bias-related brain activation abnormalities in depression (Arnold et al 2011, 268 
Hamilton and Gotlib 2008, Ramel et al 2007, van Tol et al 2012, Van Wingen et al 2010) and our previous cross-sectional 269 
observations (van Tol et al 2012), we hypothesized state-dependency of activation of the amygdala and hippocampus specific 270 
for negative valence information, and thus changes of activation as a function of symptomatic recovery. In line with this 271 
hypothesis, hippocampal reactivity during negative encoding correlated with symptomatic change. Moreover, state-dependency 272 
was observed during positive encoding. Although similar linear relations with symptomatic improvement were observed for both 273 
positive and negative encoding, changes during positive word encoding showed to be a more specific indicator of symptomatic 274 
improvement. This was indicated by the stability of effects when excluding the patients that worsened in terms of symptom 275 
severity and by the fact that the post-hoc plotting of effects indicated an increase of activation in the improved patients only. This 276 
increase followed a pattern of normalization (i.e. approaching activation in the HC). During negative encoding, associations were 277 
no longer significant when studied in the symptomatic improved patients only. This suggests that state-dependent changes 278 
during positive encoding may be a preferred marker of symptomatic improvement. Notwithstanding, although longitudinal 279 
studies did not study emotional encoding for both positive and negative information so far, our study supports findings of altered 280 
reactivity to positive information (Fu et al 2007, Victor et al 2010, Wise et al 2014), and suggests normalized reactivity to 281 
positive-related effects.  282 
The hippocampus has been proposed as a target for both anti-depressant treatment and cognitive behavioral therapy 283 
(CBT) (Goldapple et al 2004). Treatment studies have confirmed the importance of the hippocampus by consistently reporting 284 
normalization of hippocampal activation following pharmacological treatment (Anand et al 2007, Arnone et al 2012b, Fu et al 285 
2004) and CBT (Goldapple et al 2004, Ritchey et al 2011). In the current study, we studied the neural characteristics related to 286 
naturalistic changes in depressive state, which was not attributable to treatment with antidepressant medication. However, most 287 
of our sample received at least one type of psychological care. Therefore, we cannot fully rule out of the effect of psychotherapy 288 
and indeed our effects were slightly attenuated when treatment with psychotherapy was added to the model. Together, our 289 
observations suggest that increased hippocampal responsiveness to emotional material may not only reflect treatment effects of 290 
or symptomatic improvement following anti-depressants or psychological treatment(Fu et al 2007, Victor et al 2010, Wise et al 291 
2014) but also naturalistic improvement.  292 
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No other regions were found to change as a function of symptomatic improvement. Although changes in regions such 293 
as the ventromedial prefrontal cortex (Ritchey et al 2011), anterior cingulate cortex (Fu et al 2008, Fu et al 2008), frontal pole 294 
(Usami et al 2014), and the extrastriate cortex (Fu et al 2007) have been reported by previous longitudinal treatment studies. 295 
They have been reported in the context of emotional processing, but not in the context of memory formation or using verbal 296 
stimuli. Additionally, other studies have reported that prefrontal alterations might be a trait marker rather than a state marker of 297 
vulnerability to depression (Elliott et al 2012,,Tomioka et al 2015), which was not the focus of our study.  298 
A second aim of this study was to investigate whether time spent with depressive symptoms was associated with 299 
greater functional brain alterations during emotional memory encoding. We found that depression duration was not correlated 300 
with changes of activation in the hippocampus, which indicates that the neurotoxic or scarring hypothesis might not be relevant 301 
to functional changes over time. Previous cross-sectional and longitudinal studies suggested that hippocampal volume is 302 
negatively related to duration of illness in MDD, represented by history of psychiatric hospitalization (Zaremba et al 2018), 303 
number of episodes (MacQueen et al 2003, Treadway et al 2015) and duration of untreated illness (Sheline et al 1999), though 304 
not consistently (Bremner et al 2000, McKinnon et al 2009). At the same time, volumetric changes in the hippocampus have 305 
been linked to symptomatic improvement following treatment (Arnone et al 2012a), suggesting state-dependency of 306 
hippocampal volume. In the present study, though patients differed in course trajectory of depression, changes of brain 307 
activation were not related to depressive course, indicating that functional longitudinal changes observed in the hippocampus 308 
are load-independent. However, the variety in selected clinical variables of current and previous studies might explain 309 
some heterogeneity in reported results. Together, our results indicate that functional responsiveness of limbic brain regions 310 
may be more related to depressive state, without exacerbation of abnormalities as a function of unfavorable course of the 311 
depression.  312 
Some limitations of our study should be noted. First, although clear strengths of our study are its longitudinal 313 
naturalistic design and that we could control for activation changes over the same interval in a healthy sample, the associations 314 
we found between changes of brain activation and symptom change over time are correlational in nature and do not imply 315 
causation of remission in depression. And this effect was not found in a formal group  time  valence interaction. 316 
However, testing this was not the aim of our paper because we focused on changes over time within depressed 317 
patients. Second, we investigated symptom severity change of depression rather than symptom remission. Although most of 318 
our high-improved patients were recovered at the time of the follow-up measurement, our conclusions cannot be generalized to 319 
changes associated with stable remission. Third, although adding SSRI-use and psychotherapy use as covariates to the model 320 
did not change the observed relations, this does not fully rule out specific medication/treatment effects. Fourth, caution should 321 
be taken in interpreting our result as a true memory effect (i.e., hits-misses), because the number of error trials was too low to 322 
investigate this. More sensitive measures on behavioral changes in primary emotional and memory processing are necessary in 323 
future studies. Fifth, although the site effect was controlled by adding it as a covariate, it might still have confounding 324 
effect on our results. Quality assurance analysis and exploration by excluding patients that switched scanners 325 
between measurements (supplementary results) revealed similar results. These indicate that our observed effects, 326 
especially those observed during positive encoding, were not primarily driven by site-specific changes in signal over 327 
time. Next, the retrospective life chart method used to measure persistence of depressive symptoms might have been 328 
subject to patients’ mood state, though the reliability and validity have been estimated to be relatively high (Warshaw, 329 
et al 2001). Furthermore, although comorbidity of SAD and PD was similar in low and high improved MDD groups, GAD 330 
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was more frequent in low-improved MDD patients, which may have affected our results. Finally, it is possible that the 331 
encoding processing was more explicit at S2 than at S1, because people at S2 could have remembered that a recognition 332 
phase followed the encoding phase. However, implicit and explicit memory processing have been suggested to be subject to the 333 
same encoding factors and rely on similar perceptual processes and representations (Turk-Browne et al 2006), which is 334 
corroborated by the lack of differences over time in the HC group in our study.  335 
Conclusion 336 
By characterizing longitudinal changes of activation in the anterior hippocampus/amygdala during emotional memory encoding, 337 
our study showed that the neural correlates of emotional memory formation change with improvement of the depressive state. 338 
Furthermore, our findings suggest a normalization of activation especially for positive information. On the other hand, enduring 339 
depressive symptom manifestation was not related to longitudinal changes in hippocampal-amygdalar activation. Taken 340 
together, our results suggest that hippocampal activation is a state-dependent characteristic that is not related to 341 
persistence of depression. This may indicate that functional activation patterns in depression are not subject to 342 
functional ‘scarring’, a hypothesis that deserves further investigation. 343 
344 
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Tables and Figures 345 
Figure 1. Brain activation during emotional word encoding. A). Negative association between symptom change and 346 
hippocampal activation change during positive word encoding. (peak MNI coordinate: x=-27, y=-16, z=-11); B). Negative 347 
association between symptom change and hippocampal activation change during negative word encoding. (peak MNI 348 
coordinate: x=-24, y=-13, z=-11). 349 
 350 
351 
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  352 
Table 1. Demographics characteristics. 353 
 354 
355 




F t χ2 Likeliho
od ratio 
p 
N  28 19 20 - - - -  
Diagnosis over time (Remitted/non-
remitted) 
N - 17/2 9/10 - - - - - 
State change over time 
(improved/stable/worsen) 
N - 19/0/0 14/2/4 - - - - - 
Site S1(AMC/LUMC/ 
UMCG) 
N 15/9/4 8/8/3 8/8/4 - - - 1.51 .89 
Site S2(AMC/LUMC/ 
UMCG) 
N 13/11/4 7/9/3 8/8/4 - - - .70 .95 
Sex (male/female) N 10/18 7/12 9/11 - - .47 - .79 
Age  M(SD) 39.82(9.68) 37.32(9.59) 39.55(11.26) .38 - - - .68 
Years of education  M(SD) 14.46(2.77) 12.37(2.17) 13.60(3.78) 2.83 - - - .07 
Months interval  M(SD) 21.85(1.38) 22.63(1.30) 22.20(1.61) 1.66 - - - .20 
MADRS_S1 M(SD) .93(1.44) 19.11(5.17) 21.55(7.33) 127.5 - - - <.001*1 
MADRS_S2 M(SD) .50(1.00) 4.16(2.83) 17.90(6.37) 126.0 - - - <.001*2 
Relative MADRS_S2>S1 M(SD) -.81(.36) -.78(.15) -.14(.29) - -8.61 - - <.001*2 
BAI_S1 M(SD) 2.07(2.70) 12.32(7.33) 15.15(9.76) 24.83 - - - <.001*1 
BAI_S2 M(SD) 2.14(2.03) 7.58(5.61) 14.10(8.50) 26.08 - - - <.001*2 
Relative BAI_S2>S1 M(SD) .02(.99) -.45(.38) .45(1.92) - -1.89 - - .07 
Depressive duration between S1 
and S2 (%) 
M(SD) - .42(.40) .58(.40) - -1.22 - - .23 
Months with depressive symptom 
before S1 
M(SD) - 16.42(14.69) 22.85(16.28) - -1.29 - - .20 
Comorbidity_S1(MDD/MDD+)          
  Comorbid SAD N - 6/13 9/11 - - .74 - .51 
  Comorbid PD N - 6/13 6/14 - - .01 - .92 
  Comorbid GAD N - 7/12 10/10 - - 67 - .52 
Comorbidity at follow-up          
  Comorbid SAD(yes/no) N - 2/17 6/14 - - - 2.36 .13 
  Comorbid PD(yes/no) N - 2/17 6/14 - - - 2.36 .13 
  Comorbid GAD(yes/no) N - 0/19 8/12 - - - 12.66 <.01 
Age of depressive onset M(SD) - 26.89(11.27) 21.74(9.76) - 1.51 - - .14 
# of episodes prior to SI M(SD) - 1.36(.67) 1.64(.67) - -.95 - - .35 
Psychotherapy-use_S1 M(SD) - 4/15 6/14 - - - .41 .71 
Psychotherapy-use_S2 M(SD) - 9/10 6/14 - - 1.24 - .33 
Psychotherapy-use between 
S1&S2(both used/stopped after 
S1/started after S1/both not used) 
M(SD) - 10/5/0/4 12/2/2/4 - - - 4.26 .24 
SSRI-use_S1(yes/no) N - 7/12 7/13 - - 0.01 - .91 
SSRI-use_S2(yes/no) N - 7/12 3/17 - - - 2.49 .16 
SSRI-Use between S1&S2 (both 
used/stopped after S1/started after 
S1/both not used) 
N -  5/2/2/10 2/5/1/12 - - - 3.15 .37 
Benzodiazepine-use_S2 N - 4/15 3/17 - - - .24 .62 
 1. HC differed from both patient groups, while the two patient groups did not differ; 2. All groups differed from each other; 3. Infrequent use; 4. Two 
patients used benzodiazepine frequently. * significant at p<.05 
HC: healthy control; S-R: symptom-remitted MDD patients; S-S: symptomatic-symptomatic MDD patients; SAD: social anxiety disorder; PD: panic 
disorder; GAD: generalized anxiety disorder. 
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Table 2. Correlation between state-change scores and brain activation changes across patients  356 
                                                                                  MNI Coordinate 
Regions ka kb Side BA x y z T Z pFWE_SVC  
successfully encoded positive words> 
successfully encoded neutral words: 
negative correlation 
       
Hippocampus/amygdala 35 13 L 20 -27 -16 -11 3.83 3.63 .040* 
Hippocampus/amygdala 33 9 R 34 27 -4 -11 3.46 3.31 .107 
           
successfully encoded negative words> 
successfully encoded neutral words: 
negative correlation 
        
Hippocampus/amygdala 50 22 L - -24 -13 -11 3.76 3.57 .049* 
Hippocampus/amygdala 59 20 R - 15 -7 -17 3.40 3.26 .122 
a. Cluster size in whole-brain analysis; b. Cluster size after small volume correction. 357 
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Supplementary methods  
fMRI data acquisition and processing. A SENSE-6 channel head coil was used at S1 in Amsterdam. A SENSE-8 channel 
head coil was used in Groningen and Leiden at both S1 and S2 and in Amsterdam at S2. In Groningen, echo planar imaging 
(EPI) volumes of 39 slices were acquired using a T2*- weighted gradient echo sequence (TR=2300 ms, TE=28 ms, matrix size: 
64 × 64, plane resolution: 3 × 3 mm, slice thickness: 3 mm) at S1 and the EPI slice setting was changed into 35 slices at S2. In 
Leiden and Amsterdam, 35 axial slices were obtained using a T2*- weighted gradient echo sequence (TR=2300 ms, TE = 30 
ms, matrix size: 96 × 96, plane resolution: 2.29 × 2.29 mm, slice thickness: 3 mm) at S1 and S2. Transversal slices were 
acquired parallel to the anterior commissure-posterior commissure plane (no gap) in interleaved order.  
In addition, a high-resolution anatomical MRI was obtained with a sagittal 3D gradient-echo T1-weighted sequence for 
each participant (TR=9 ms, TE=3.5 ms, matrix size: 256 × 256, voxel size: 1 × 1 × 1 mm, 170 slices). 
Before preprocessing, functional images were reoriented manually to the anterior-posterior commissure plane. 
Preprocessing consisted of slice timing, spatial realignment and co-registration of the anatomical image to the EPI image, 
spatial normalizing of the image to the standard Montreal Neurological Institute (MNI) space, reslicing to a 3 × 3 × 3 mm voxel 
size and spatial smoothing with an 8 mm full-width at half maximum Gaussian kernel. To remove low frequency noise, a high-
pass filter with a cut-off of 128 s was applied to the fMRI time-series. 
For the first-level analyses, two first-level models were set up for each participant, one for S1 and one for S2. To 
minimize the effect of motion, the absolute scan-to-scan difference for rotational and translational displacement after 
realignment was computed, and scans in which the displacement was larger than 0.9 mm compared to the previous scan were 
censored by modeling these as individual regressors 40. Because we were interested in the valence effects and to be consistent 
with our previous reports 4,10, we defined the following contrasts for each model: [successfully encoded positive words > 
successfully encoded neutral words; positive>neutral encoding] and [successfully encoded negative words > successfully 
encoded neutral words; negative>neutral encoding]. The difference between the two scan sessions was calculated for each 
contrast by subtracting the contrast image of the first scan from the second scan (S2-S1) for every participant using the ImCalc-
option implemented in SPM8. Consequently, positive activation indicates an increase of activation from S1 to S2 and negative 
activation a decrease of activation from S1 to S2.  
 
Post hoc group comparison. Because effects were observed during both positive and negative vs. neutral encoding, we 
decided to post-hoc evaluate the dependency of observed effects on changes in neutral or emotional word encoding. To this 
end, we built a full-factorial model with S2-S1 contrast maps as dependent variables, in which valence 
(positive/neutral/negative>baseline) was entered as within-subject factor (with three levels) and symptom change as interacting 
factor with valence. No correlation was found between brain activation during neutral>baseline and symptomatic change 
(Supplementary Figure S2), however neither for negative > baseline and positive > baseline. It appeared that the change of 
brain activation depended on the difference between emotional and neutral encoding, as contrasting change in relation to 
positive and neutral encoding (>baseline), and negative and neutral (> baseline) encoding again showed effects in the left 
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hippocampus ([positive<neutral, MNI coordinates [x=-27, y=-16, z=-11], Z=4.00, pFWE =.010; negative<neutral, MNI coordinates 
[x=-24, y=-16, z=-11], Z=3.63, pFWE=.031).  
In addition, to explore the change in HC group over time and to illustrate whether changes in patients reflect normalization, 
we built a group (HC, HI, LI) x valence (positive>neutral, negative>neutral) x time (S1, S2) model. Activation estimates from the 




Demographic characteristics. Within patients, symptom change was not associated with age (r=.28, p=.08), years of 
education (r=.14, p=.38) or sex (t=.39, p=.70). Moreover, symptom change was not associated with medication use (F(3, 
39)=.89, p=.46) or psychotherapy use (F(3,39)=.61, p=.61) at S1 or S2. In addition, symptom change was not related to anxiety 
severity at S1 (BAI-score S1; r=-.03, p=.85) and depressive load in the five years before S1 (r=.20, p=.22), but trend-wise 
related to depression duration between S1 and S2 (r=.29, p=.07). Symptom change of depression was correlated to change in 
anxiety severity (BAI-scores) (r=.46, p=.003) and depression severity at baseline (MADRS-S1; r=-.34, p=.034). 
 
fMRI results:  
Post hoc group comparison: group (HC, HI, LI) x valence (positive>neutral, negative>neutral) x time (S1, S2) . Plotting of 
these estimates indicated no change in our main cluster in HC, and further indicated that changes followed a trend of 
normalization during positive but not negative word encoding (Supplementary Figure 3A & 3B). No interaction of time by valence 
or main effect of valence was observed in HC. A main effect of time in HC was observed subthreshold anterior ([x=-15,y=-10,z=-
17], Z=3.49, pFWE =.07). 
 
Correlations with depression duration and course. To describe depression course in between two scan sessions, remitters 
(n=11), non-remitters (n=18) and recurrent group (n=10) was defined based on life chart interview. Patients who satisfied the 
following criteria were defined as remitters: 1) more than 3 months without symptoms or symptoms without burden within 1 year 
after S1, 2) without recurrence in the follow-up period. Patients who have a recurrence of symptoms for at least 1 month with 
burden after firstly obtaining remission were classified into recurrent group. Patients who had symptoms with burden in every 
month following S1 during the entire follow-up period were defined as non-remitters.  
To explore whether changes in brain activation correlated with depressive course in between measurements, we divided 
our patients into remitters (n=11), non-remitters (n=18) and recurrent group (n=10) based on the pattern of presence of 
symptomatology between two scan sessions. However, course trajectory was not related to activation change during both 
positive and negative (>neutral) word encoding. 
 
Quality assurance analysis. To control for possible bias or systematic effects across the scanning sites, we conducted 
a quality assurance analysis using MRI Quality Control tool (MRIQC) (Esteban et al 2017). From these reports, we 
specifically focused on the signal-to-noise ratio on source data from subjects, whom did not change scanning site 
(n=34). We built a repeated measures ANOVA with site (3; AMC, LUMC, UMCG) as a between-subject factor and 
scanning time (2; S1, S2) as a within-subject factor. We found a significant interaction between site and time (F2,57=3.88, 
p=.03) and a significant main effect of site (F2,57=4.80, p=.01). No main effect of time was found (Figure S4). Post-hoc 
analysis showed the site effect was significant at S1 but the difference was not significant at S2. The time effect was 
found in UMCG participants but not at the other two sites. Consequently, we performed a second test by excluding 
participants from UMCG (n=11). The main results did not change during positive words encoding (PFWE=.032, t=4.00, 
Z=3.70, MNI coordinates [x=-27, y=-13, z=-11]) but became sub-threshold during negative words encoding (PFWE=.120, 
t=3.47, Z=3.26, MNI coordinates [x=-24, y=-13, z=-11]). 
 
Control for site effects. To test if the results were influenced by changes of scanner sites, we repeated the analyses 
after excluding all participants who switched scanning site at S2 (n=5). The results showed that the correlation 
between changes of depressive state and brain activation change during positive emotional words encoding did not 
change (PFWE=.028, t=3.97, Z=3.73, MNI coordinates [x=-27, y=-13, z=-11]), indicating that reported effects were not 
affected by changing scanning site. The correlation during negative words encoding became sub-threshold (PFWE=.099, 
t=3.49, Z=3.32, MNI coordinates [x=-30, y=-16, z=-23]). 
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Supplementary Table S1. Use of medication between two scan sessions. 
 High-improved Low-improved Likelihood ratio p 
Benzodiazepine(yes/no) 3/16 5/15 .07 .79 
Anti-depressants  1/18 0/20 1.52 .48 
SSRIs 2/17 3/17 .13 .71 




Supplementary Table S2. Main effect of task of emotional memory task with an initial threshold of p<.005 uncorrected. 
                                                                                  MNI Coordinate 
Regions k  Side BA x y z F Z puncorrected  
Main effect of task           
Inferior frontal gyrus 488  L  -51 32 16 17.40 5.05 <.001 
Medial frontal gyrus 38  L  -3 29 46 7.17 3.05 <.001 
Superior frontal gyrus 60  L  -21 47 40 11.19 3.98 <.001 
Middle temporal gyrus 17  L  -60 -43 -2 10.12 3.76 <.001 
Middle temporal gyrus   R  48 -1 -16 8.29 3.34 <.001 
Temporal pole 22  L  -48 11 -23 11.26 3.99 <.001 
Lingual gyrus 60  L  -12 -40 -5 9.75 3.68 <.001 
Lingual gyrus 58  R  9 -34 -8 9.58 3.64 <.001 
Hippocampus 23  R  18 -23 -8 8.68 3.43 <.001 
Hippocampus 7  L  -18 -10 -11 7.67 3.18 <.001 
 
Supplementary Table S3. Main effect of valence and symptom change in main analysis 
                                                                  MNI Coordinate 
Regions ka kb Side BA x y z T Z pFWE_SVC  
Main effect of valence           
Inferior frontal gyrus 143 - L 45 -51 32 19 28.62 4.74 .027* 
           
Main effect of symptom change           
Hippocampus/amygdala 17 5 L 20 -24 -13 -11 17.79 3.80 .026* 
a. Cluster size in whole-brain analysis; b. Cluster size after small volume correction. 
* Significant at p<.05 FWE corrected, voxel-level after small volume correction (SVC). 
 
Supplementary Table S4. Effects from group  time  valence model 
                                                            MNI Coordinate 
Regions k Side BA x y z F Z Puncorrected  
Interaction of group x time          
Inferior frontal gyrus 11 R 44 57 17 31 10.10 3.84 <.001 
Hippocampus/amygdala 19 R 35 18 -10 -17 9.46 3.70 <.001 
Interaction of group x time x valence          
Inferior frontal gyrus 7 R 45 56 26 25 8.31 3.41 <.001 
Lingual gyrus 6 R 18 12 -49 4 8.29 3.41 <.001 
 
 
Supplementary Figure S1. Flow chart of recruitment and sample selection of participants. At baseline measurement (S1), 
117 MDD patients and 52 healthy controls had valid scans during emotional words encoding task. From 53 of these 
patients and 13 of healthy controls the second measurement data (S2) could not be included because of loss to follow-
up or missing behavioral data. Moreover, at S1 25 patients were not depressed at time of scanning (MADRS 10), one 
patients with too high MADRS score and 11 healthy controls were excluded to obtain a good match with the included 
patients. One patient was excluded based on the relative change of depressive symptom exceeded 3 standard 
deviation. In total, 21 symptom-improved patients, 19 non-improved patients and 29 healthy controls were included in the final 
analysis.  
MDD: major depressive disorder; MDD+: depression combined with an additional diagnosis of social anxiety disorder, panic 
disorder and/or generalized anxiety disorder; ANX, anxiety; S1, baseline measurement; S2, second measurement; MADRS, 
Montgomery–Åsberg Depression Rating Scale; HC, healthy control; S-R: symptomatic-remitted MDD patients; S-S: 
symptomatic-symptomatic MDD patients. 
Supplementary Figure S2. No correlation of change in the hippocampus/amygdala and symptom change in MDD was found 
between brain activation during neutral>baseline and symptomatic change. 
 
 
Supplementary Figure S3. Activation of the left hippocampal/amygdala extracted from correlation analysis during A) positive 











We are grateful for the reviewers’ time and their insightful comments on our 
manuscript on longitudinal changes of brain activation in depression.  
We carefully revised the manuscript and addressed each comment raised by the 
reviewers. Below you can find an overview of the comments, with our point by point 
responses. Changes in the manuscript are in bold font. 
 
Reviewer #1: This longitudinal study aimed at assessing the impact of changes in 
depressive severity on hippocampal and amygdalar activation during memory 
encoding. The paper is overall very well written. However, I think it would benefit from 
a few clarifications: 
 
1.1 The sentence on page 4 "no specific treatment was delivered but treatment 
delivery was monitored" seems contradictory. I suggest rephrasing. 
 
Reply to 1.1: We thank the reviewer for his/her thoughtful comments. We agree that 
the sentence could lead to confusion. We meant to underline that treatment was not 
offered as part of the study but the treatment that patients received anyhow was 
reconstructed as part of this naturalistic longitudinal cohort study. We rephrased the 
sentence in our introduction, which now reads (cf. Introduction, page4, line77-79): 
“In this interval, no specific treatment was delivered as part of the study protocol. 
no specific treatment was delivered, but Given the naturalistic design of our 
study, participants could receive treatment as usual, which was reconstructed 
retrospectively based on self-reports at the two-year follow-up interview.”  
 
1.2 Can the authors give more details with respect to comorbidity status (e.g. how 
many people had comorbid generalized anxiety, social anxiety, panic disorder at S1 
and S2? What was the reason for allowing comorbidity? Did the comorbidity status, 
change over time, from S1 to S2? Were symptoms measured for the additional 
comorbid conditions and considered in the analysis? 
 
Reply to 1.2: Comorbidity was allowed because NESDA specifically aimed to gain 
insight into the long-term course of depression and anxiety disorders, which are highly 
comorbid and may share neural underpinnings. Previously we reported on 
cross-sectional commonalities in the neural correlates of emotional word processing 
amongst patients with depression and anxiety disorders in this sample (e.g. van Tol et 
al. 2012, Biol Psychiatry). Only comorbidity of generalized anxiety disorder, social 
anxiety, and/or panic disorder was allowed in the NESDA Neuroimaging study. In the 
current analyses, we were interested in the long-term effects of depression 
persistence on the neural correlates of emotional word processing for later recognition. 
We controlled in our analyses for the presence of comorbid anxiety status by 
measuring anxiety state using BAI scores and including relative change of BAI scores 
in the analyses. We now listed the details of comorbidity status at follow-up and their 
Response to Reviewers
change over time in the table below: 
 
We observed that comorbidity of MDD with SAD and PD did not differ between low 
and high improved MDD patients at S1, though GAD at time of follow up was only 
present in the low improved group. We therefore added to our discussion a comment 
that our results could be potentially affected by comorbidity status, in particular GAD. 
 
Adjustment in the manuscript: 
(cf. Discussion, page11, line330) “Furthermore, although comorbidity of SAD and 
PD was similar in low and high improved MDD groups, GAD was more frequent 
in low-improved MDD patients, which may have affected our results.” 
 
1.3 The reason for including some medication use and drawing the line for certain 
dosage is not very well explained. What was the reason for accepting SSRIs and 
benzodiazepines only? How rigid was this selection and why? Even though in small 
numbers, the supplementary material shows the use of SNRIs, as well as "other 
antidepressants". What was the rationale for choosing the cut-off point of 20 mg of 
benzodiazepine up to 3 times/week?  
 
Reply to 1.3: We chose not to aim for medication-free participants only, to ensure that 
the patients participating in the MRI sub-study were a representative sample of the 
overall NESDA cohort. However, psychotropic medication was limited to stable use of 
SSRI’s and/or infrequent use of benzodiazepines, equivalent to 20mg oxazepam (the 
most widely prescribed anxiolytic drug in the Netherlands) three times a week or less. 
This was done to reduce variance associated with use of e.g. tricyclic antidepressants, 
MAO-inhibitors or atypical antipsychotics (i.e., SSRI’s only) and because 
frequent/chronic benzodiazepine use is a likely confound when presenting ‘emotional’ 
stimuli (words or faces). Therefore, participants were requested to abstain from 




F t χ2 Likeliho
od ratio 
p 
N  28 19 20 - - - -  
Comorbidity_S1          
  Comorbid SAD(yes/no) N - 6/13 9/11 - - .74 - .51 
  Comorbid PD(yes/no) N - 6/13 6/14 - - .01 - .92 
  Comorbid GAD(yes/no) N - 7/12 10/10 - - 67 - .52 
Comorbidity at follow-up          
  Comorbid SAD(yes/no) N - 2/17 6/14 - - - 2.36 .13 
  Comorbid PD(yes/no) N - 2/17 6/14 - - - 2.36 .13 
  Comorbid GAD(yes/no) N - 0/19 8/12 - - - 12.66 <.01 
 1. HC differed from both patient groups, while the two patient groups did not differ; 2. All groups differed from each other; 3. Infrequent use; 4. Two patients 
used benzodiazepine frequently. * significant at p<.05 
HC: healthy control; S-R: symptom-remitted MDD patients; S-S: symptomatic-symptomatic MDD patients; SAD: social anxiety disorder; PD: panic 
disorder; GAD: generalized anxiety disorder. 
benzodiazepine use 48 hours prior to scanning. The reviewer correctly notes that at 
S2, three patients used SNRIs: this was due to the observational nature of the NESDA 
study in which ‘treatment as usual’ was permitted, without study-specific treatment 
guidelines (cf. our reply to 1.1).   
 
 
1.4 I am unclear how the percentage of time spent with depression and presence of 
depressive symptoms per month between S1 and S2 was measured. What exactly 
was recorded in the life chart review, how often, by whom etc. Was it all assessed at 
S2? If yes, did the authors consider a recall bias? This was not mentioned in the 
limitations. 
 
Reply to 1.4: The Life Chart Method (LCM) was administered at S2 by trained 
professionals to retrospectively assess presence and severity of symptoms. The LCM 
starts with exploring the presence of life events in a certain period to refresh memory. 
Subsequently, presence and severity of depressive symptoms (no burden, small 
burden etc.) is assessed (Lyketsos, et al 1994). For each participant, the total number 
of months with depressive symptoms with at least small burden within the follow-up 
period was computed. The life chart interviews were performed at both the baseline 
and two-year follow-up interview session. The baseline LCM was used to determine 
the presence of symptoms in the five years (per year) prior to baseline. The follow-up 
LCM administered at the two-year follow-up interview was used to calculate 
percentage of time spent with depression during this two-year-course. The validity 
and reliability of its methodology have been shown to be good among patients 
(Warshaw, et al 2001). 
Nevertheless, we agree that retrospective reports could be subject to recall bias. 
We now acknowledged this possible limitation in the Discussion section. 
 
Adjustment in the manuscript: 
(cf. Methods and Materials, page6, line155) “Percentage of months experiencing 
depressive symptoms relative to the overall follow-up period was calculated per 
patient as time spent with depression (Ai et al 2015).” 
 
(cf. Discussion section, page11, line328-330) “Next, the retrospective life chart 
method used to measure persistence of depressive symptoms might have been 
subject to patients’ mood state, though the reliability and validity have been 
estimated to be relatively high (Warshaw, et al 2001).” 
 
1.5 After the sensitivity analysis was done, it seems that 6 more patients were 
excluded. What was the final number of patients in each of the groups 
 
Reply to 1.5: In the main analyses, we performed all analyses on all depressed 
patients, which included patients who were equally or more depressed at S2 than at 
S1. As a reliability check, we did the sensitivity analyses for both behavioral and fMRI 
data only within patients who showed symptomatic improvement. Consequently, the 
sample size for the continuous sensitivity analysis changed from 39 to 33. The 
sensitivity analyses were thus only performed for the continuous analyses, and not for 
the group analyses. 
 
Adjustment in the manuscript: 
(cf. Method, page 7, line194-195) “A sensitivity analysis was planned to test whether 




1.6 In the discussion the authors also mention that "no other regions were found to 
change as a function of symptomatic improvement". Did they actually explore this as 
well? The introduction states that they mostly focused on activation of the amygdala 
and hippocampus. 
 
Reply to 1.6: Indeed, our regions of interests were the amygdala and hippocampal 
areas and in addition we explored effects using whole-brain analyses. This means 
that due to our specific hypotheses, we a priori considered effects occurring in these 
regions significant at p<.05 FWE corrected for the extent of a spatial mask 
encompassing all voxels covering the bilateral hippocampi and amygdalae. 
Nevertheless, we explored whether activation in other voxels outside these regions 
were additionally associated with severity and time spent with depressive symptoms. 
For effects occurring outside the amygdala and hippocampus we set the threshold 
p<.05, FWE whole-brain corrected, but no areas survived. We now make this more 
explicit in our introduction and methods. 
 
Adjustments in the manuscript  
(cf. Introduction, page4, line81-82): “We further aimed to Furthermore, we aimed to 
explore whether activation in other brain regions other than amygdala and 
hippocampus (such as ventromedial prefrontal cortex, anterior cingulate cortex and 
frontal pole) related to longitudinal treatment responses was associated with severity 
and time spent with depressive symptoms.” 
 
(cf. Methods, page8, line213): “We also examined the effects in other brain 
regions than ROIs, which Effects occurring outside the amygdala and 
hippocampus had to meet p<.05, FWE whole-brain corrected to be considered 
significant.” 
 
1.7 I am not convinced that showing how emotional memory formation is sensitive to 
changes in depression severity, can justify the conclusion that hippocampal and 
amygdalar brain activation is not subject to functional scarring. Would one single 
study, with all the listed limitations, be able to support such a claim? 
 
Reply to 1.7: These conclusions were based on results from two main analyses: 1) 
We found that brain activation changes in the hippocampus and amygdala were 
associated with changes in depression severity, which suggested state-dependency 
of these functional abnormalities in depression; 2) We found no relation between time 
spent with depression and activation changes in the hippocampus and amygdala, 
which we interpreted as an indication that functional abnormalities are not associated 
with longer depressive duration and therefore are not subject to ‘functional scarring’.  
We agree, however, that these conclusions are based on a single study (with 
limitations) and clearly in need of replication. We therefore have toned down this 
conclusion, which now reads (cf. Conclusion, page 12, line339): “Taken together, our 
results suggest that hippocampal activation is a state-dependent characteristic that 
is not related to persistence of depression. This may indicate that functional 
activation patterns in depression are not subject to functional ‘scarring’, a 
hypothesis that deserves further investigation.” 
 
Adjustments in the manuscript 
(cf. Abstract, page2, line33-36): “Conclusion: Using a longitudinal within-subjects 
design we showed that hippocampal-amygdalar activation during emotional memory 
formation is related to depressive symptom severity but not persistence (i.e. time 
spent with depression or ‘load’) was not associated with activation changes over 
time, suggesting functional activation patterns in depression that hippocampal 
and amygdalar brain activation are not subject to functional ‘scarring’ although this 
hypothesis awaits future replication.” 
 
Reviewer #2: In the study "Longitudinal brain changes in MDD during emotional 
encoding", the authors investigated if changes in brain activation during emotional 
encoding was associated with symptomatic improvement and persistence of 
depressive symptoms. This research question of great importance because it remains 
unclear from previous studies if functional changes in patients with MDD are 
state-dependent or not. Therefore, the authors conducted a 2-year follow-up 
longitudinal study with MRI measurements at both time-points. Furthermore, 
pharmacological treatment and psychotherapy during the follow-up interval were 
monitored and included in statistical analyses, which is a major strength of the study. 
Apart from the important research question and the selection of a well-suited study 
design, the manuscript is also well written. 
 
Although the statistical models are well suited to answer the research questions, the 
results (of both main and supplementary analyses) should be reported conclusively 
with a systematic presentation of all main effects and interactions. Furthermore, the 
authors should comment on the signal stability over time. Because data was acquired 
at different scanners and some participants even switched scanning site from 
baseline to follow-up, I am concerned how reliable contrast maps between follow-up 
and baseline fMRI are. 
 
2.1 Introduction 
 Second paragraph: the authors may consider citing other interventions than 
psychotropic medication such as electroconvulsive therapy when discussing the 
effects of treatment on amygdalar and hippocampal activation (e.g. Redlich et al., 
2017). 
 
Reply to 2.1: We thank the reviewer for taking time to thoroughly review our 
manuscript and pointing out important issues. We agree that effects of ECT on MTL 
activation deserve mentioning and have adapted our Introduction as follows 
(Introduction, page3, line55):  
 
“Findings have been inconclusive with reports of decreased (Fu et al 2004, Sheline 
et al 2001, Redlich et al 2017), increased (Goldapple et al 2004, Neumeister et al 
2006, Ritchey et al 2011, Victor et al 2010), or unchanged (Fu et al 2015, Opmeer et 
al 2015) activation following successful short-term pharmacological treatment (Fu et 
al 2004, Sheline et al 2001, Victor et al 2010,,Fu et al 2015), electroconvulsive 
therapy (Redlich et al 2017), cognitive behavioral treatment (Fu et al 2008, 









2.2.1 The information about how experimental conditions were contrasted for fMRI 
analyses should be stated more explicitly in the main body of the manuscript, not only 
in the supplementary materials. The wording "positive > neutral" and "negative > 
neutral" is misleading because the authors have investigated only successfully 
encoded stimuli based on the recognition task. Please include this information in the 
methods section.  
 
Reply to 2.2.1: Indeed, we only investigated successfully encoded stimuli during the 
memory encoding phase. We adapted the relevant wording in our manuscript 
accordingly. 
 
Adjustments in the manuscript: 
(cf. Methods session, page7, line179) “To test for the association between symptom 
change and change of brain activation during positive and negative encoding over the 
two-year interval, scan moments, S2-S1 contrast maps were entered as dependent 
variables in a full-factorial model, with valence (successfully encoded positive 
words>successfully encoded neutral words positive>neutral encoding [S2-S1], 
successfully encoded negative words>successfully encoded neutral words 
negative>neutral encoding [S2-S1]) as a factor and symptom change ([MADRS S2 
– MADRS S1]/MADRS S1) as interacting factor with valence.” 
 
(cf. Methods session, page8, line198) “We built a full factorial model with valence as 
factor (2; successfully encoded positive words>successfully encoded neutral 
words and successfully encoded negative words>successfully encoded neutral 
words positive>neutral and negative>neutral) and time spent with depressive 
symptoms as an interacting covariate with valence.” 
 
(cf. Results session, page9, line238) “Adding time spent with depressive symptoms in 
the interval between S1 and S2 as covariate did not change the results (Z=3.85, 
pFWE=.019 for successfully encoded positive words>successfully encoded 
neutral words positive>neutral encoding (pos); Z=3.95, pFWE=.014 for 
successfully encoded negative words>successfully encoded neutral words 
negative>neutral encoding (neg)).” 
 
(cf. Results session, page9, line252) “No correlation between percentage of time with 
depressive symptoms and changes in brain activation was observed across all MDD 
patients during successful encoding of positive and negative words. 






2.2.2 Although the authors included covariates of no interest to account for 
participants who switched scanning sites during the study protocol, I am still 
concerned about the data quality and reliability of follow-up measurements from 
different scanners. The authors mention "minor" variations in sequence and coil but 
do not comment on assurance of signal stability and reliability. Has there been any 
protocol for MRI quality assurance? 
Because the authors calculated contrast maps to indicate change in brain activation, it 
would be important to comment on scanner/signal stability over time and between 
scanning sites. I also suggest to exclude all participants who changed scanning site at 
follow-up from the analyses to see if the reported effects are independent of scanning 
site (if so, these analyses may be shifted to the supplementary materials). 
 
Reply to 2.2.2: We agree with the reviewer that signal stability and reliability is very 
important to check in longitudinal studies. We took a number of measures to 
investigate how scanner variability and signal stability over time could have affected 
our results. 
First, to explore how changing scanners affected the results, we excluded all 
participants who changed scanning site (n= 5) and repeated the analyses. The results 
showed that the correlation between brain activation change and positive emotional 
words encoding did not change (PFWE=.028, t=3.97, Z=3.73, MNI coordinates [x=-27, 
y=-13, z=-11]), indicating that reported effects were not affected by change in 
scanning site. The correlation during negative words encoding however became 
sub-threshold (PFWE=.099, t=3.49, Z=3.32, MNI coordinates [x=-30, y=-16, z=-23]).  
Furthermore, to check the signal stability and reliability, we did a MRIQC analysis 
with data of subjects whom did not change scanning site over time (n=34). After we 
calculated the signal-to-noise ratio (SNR) on the raw data, we built a repeated 
measures ANOVA with site (3; AMC, LUMC, UMCG) as a between-subject factor and 
scanning time (2; S1, S2) as a within-subject factor. There was a significant 
interaction between site and time (F2,57=3.88, p=.03) and a significant main effect of 
site (F2,57=4.80, p=.01). No main effect of time was found. Post-hoc analysis showed 
the site effect was significant at S1 but the difference was not significant at S2. 
Specifically, SNR at UMCG showed significant differences with SNRs at AMC (p=.011) 
and LUMC (p=.044). Also, post-hoc analysis showed a time effect for SNR at UMCG 
scans only. These results led us to perform the following sensitivity analyses in our 
main analyses :1) we controlled for site by adding four dummy variables (i.e., both 
time scanned in AMC; changed from AMC to LUMC; changed from LUMC to AMC; 
both time scanned in UMCG; both time scanned in LUMC) and as shown in our 
original submission, this did not affect our main results, 2) Next we excluded all 
subjects from the UMCG (n=11) to explore if main effects would be affected by this. 
The main results did not change during positive words encoding (PFWE=.032, t=4.00, 
Z=3.70, MNI coordinates [x=-27, y=-13, z=-11]) but became sub-threshold during 
negative words encoding (PFWE=.120, t=3.47, Z=3.26, MNI coordinates [x=-24, y=-13, 
z=-11]). 
In summary, the MRIQC analyses therefore showed that in Leiden and 
Amsterdam, the signal was fairly stable, though in Groningen SNR slightly dropped in 
the 11 participants included at that site (Fig S4). However, excluding these patients 
from the main analysis still indicated an effect during positive word encoding and a 
slightly weaker effect during negative encoding, which could also relate to loss of 
power. We therefore think that our observations, especially those observed during 
positive encoding, were not primarily driven by site-specific changes in signal over 
time. We added these analyses to supplementary results and discussed the scanner 
change and signal stability as limitations. 
 
Adjustments in the manuscript: 
(cf. Discussion, page11, line324) “Fifth, although the site effect was controlled by 
adding it as a covariate, it might still have confounding effect on our results. 
Quality assurance analysis and exploration by excluding patients that switched 
scanners between measurements (supplementary results) revealed similar 
results. These indicate that our observed effects, especially those observed 
during positive encoding, were not primarily driven by site-specific changes in 
signal over time.” 
 
(cf. Supplementary results) “Quality assurance analysis. To control for possible 
bias or systematic effects across the scanning sites, we conducted a quality 
assurance analysis using MRI Quality Control tool (MRIQC) (Esteban et al 2017). 
From these reports, we specifically focused on the signal-to-noise ratio on 
source data from subjects, whom did not change scanning site (n=34). We built 
a repeated measures ANOVA with site (3; AMC, LUMC, UMCG) as a 
between-subject factor and scanning time (2; S1, S2) as a within-subject factor. 
We found a significant interaction between site and time (F2,57=3.88, p=.03) and a 
significant main effect of site (F2,57=4.80, p=.01). No main effect of time was 
found (Figure S4). Post-hoc analysis showed the site effect was significant at 
S1 but the difference was not significant at S2. The time effect was found in 
UMCG participants but not at the other two sites. Consequently, we performed a 
second test by excluding participants from UMCG (n=11). The main results did 
not change during positive words encoding (PFWE=.032, t=4.00, Z=3.70, MNI 
coordinates [x=-27, y=-13, z=-11]) but became sub-threshold during negative 
words encoding (PFWE=.120, t=3.47, Z=3.26, MNI coordinates [x=-24, y=-13, 
z=-11]). 
 
Control for site effects. To test if the results were influenced by changes of 
scanner sites, we repeated the analyses after excluding all participants who 
switched scanning site at S2 (n=5). The results showed that the correlation 
between changes of depressive state and brain activation change during 
positive emotional words encoding did not change (PFWE=.028, t=3.97, Z=3.73, 
MNI coordinates [x=-27, y=-13, z=-11]), indicating that reported effects were not 
affected by changing scanning site. The correlation during negative words 
encoding became sub-threshold (PFWE=.099, t=3.49, Z=3.32, MNI coordinates 
[x=-30, y=-16, z=-23]).” 
 
 
2.2.3 The authors report that they performed separate analyses for the positive and 
negative condition with regard to the effects of persistence of depressive symptoms. It 
seems to me that the same holds true for the effects of change of depressive state, 
but this information is not clear to me from the methods section. Please clarify. 
 
Reply to 2.2.3: Indeed, the analyses on effect of change of depressive state were 
also conducted for positive and negative words encoding separately. We now made 
clarified this issue in the methods session, which now reads: 
(cf. page7, line182) “Contrast maps were built for successful encoding of 




2.3.1 In the results, the authors report a negative correlation between symptomatic 
improvement and both positive and negative word encoding. If both conditions show a 
correlation with symptomatic improvement separately, the main effect of symptomatic 
improvement should be significant as well. Please report the main effect of 
symptomatic improvement (irrespective of condition).  
Please also report the main effect of valence and the interaction of valence x 
symptom change. 
 
Reply to 2.3.1: In our main analysis, we built the correlation model with valence as a 
factor and symptom improvement as an interacting factor with valence, which allowed 
us to investigate the effect of symptom change on positive and negative condition 
separately and may reflect the interaction between symptom change and valence.  
In our revision, we built a new model in order to report the main effects of valence and 
symptom change, with these two variables as two independent (non-interacting) 
factors. The results were listed below and added to the supplementary table (S3). 




                                                                  MNI Coordinate 
Regions ka kb Side BA x y z T Z pFWE_SVC  
Main effect of valence           
Inferior frontal gyrus 143 - L 45 -51 32 19 28.62 4.74 .027* 
           
Main effect of symptom change           
Hippocampus/amygdala 17 5 L 20 -24 -13 -11 17.79 3.80 .026* 
a. Cluster size in whole-brain analysis; b. Cluster size after small volume correction. 




2.3.2 MNI coordinates given in Figure 1 do not correspond to the cluster coordinates 
given in Table 2. However, the authors state that the voxels selected for Figure 1 are 
the peak voxels derived from the correlations of symptom change and brain activation. 
Which coordinates are shown in Table 2? Please clarify. 
 
Reply to 2.3.2: After we double-checked the peak coordinates and figure images, we 
found that the peak voxel in the results table (Table 2) during successful encoding of 
positive words should be updated as [-27, -16, -11] and the peaks in the legend of 
Figure 1 should be [-27, -16, -11] and [-24, -13, -11]. Despite the inconsistency in the 
legend, the coordinates were correctly presented. We apologize for any confusion 
resulting from the inconsistency between the legend of Figure 1 and Table 2. 
 
Adjustments in the manuscript: 
(c.f. Figure 1. Legend) “Brain activation during emotional word encoding. A). Negative 
association between symptom change and hippocampal activation change during 
positive word encoding. (peak MNI coordinate: x=-28-27, y=-13-16, z=-11); B). 
Negative association between symptom change and hippocampal activation change 
during negative word encoding. (peak MNI coordinate: x=-23-24, y=-13, z=-11).” 
 
(cf. Table 2) 
Table 2. Correlation between state-change scores and brain activation changes across patients  
                                                                  MNI Coordinate 
Regions ka kb Side BA x y z T Z pFWE_SVC  
Positive>neutral successfully 
encoded positive 
words>successfully encoded neutral 
words: 
negative correlation 
          
Hippocampus/amygdala 35 13 L 20 -23-27 -18-16 -11 3.83 3.63 .040* 
Hippocampus/amygdala 33 9 R 34 27 -4 -11 3.46 3.31 .107 
           
Negative>neutral successfully 
encoded negative 
words>successfully encoded neutral 
words: 
negative correlation 
          
Hippocampus/amygdala 50 22 L - -24 -13 -11 3.76 3.57 .049* 
Hippocampus/amygdala 59 20 R - 15 -7 -17 3.40 3.26 .122 
 
 
2.3.3 In the supplementary materials, the authors report a group x time x valence 
ANCOVA for the fMRI data. Why did you choose time as a within-subject factor 
instead of using S2-S1 contrast maps as in your correlational analyses? Please also 
report the interaction of group x time (if you stay with time instead of using contrast 
maps) and the three-way interaction of group x time x valence to see if the three 
groups (HC, HI, LI) show different trajectories of brain activation in response to 
positive and negative words. 
I would expect to find F- and p-values for main effects and all possible interactions 
from voxelwise analyses within the hippocampus and amygdala ROI (as for the 
primary analyses, defined by WFU pickatlas). Instead, the authors extracted 
activation estimates from clusters derived by preceding correlational analysis. 
However, the MNI coordinates given in Supplementary figure S3 do not correspond to 
the cluster coordinates in Table 2. This procedure for supplementary analyses seems 
like double dipping to me, please comment on this. 
 
Reply to 2.3.3: The aim for building a group  time  valence model was to follow-up 
our continuous analyses to additionally examine the change in HC group over time 
and to illustrate whether changes in the clusters resulting from our correlation analysis 
in patients reflected normalization. We now added the interaction of group  time and 
interaction of group  time  valence in the supplementary Table. 
 
Of note, we only plotted the effects in patients and HCs for the purpose of 
illustrating the normalization. Also, despite that we found state-dependency of brain 
activation during emotional word encoding within patients, we did not observe this 
from a formal group  time  valence interaction. However, investigating this was not 
the aim of our study, because we aimed to investigate changes over time within 
depressed patients. 
 
                                                            MNI Coordinate 
Regions k Side BA x y z F Z Puncorrected  
Interaction of group x time          
Inferior frontal gyrus 11 R 44 57 17 31 10.10 3.84 <.001 
Hippocampus/amygdala 19 R 35 18 -10 -17 9.46 3.70 <.001 
          
Interaction of group x time x valence          
Inferior frontal gyrus 7 R 45 56 26 25 8.31 3.41 <.001 
Lingual gyrus 6 R 18 12 -49 4 8.29 3.41 <.001 
 
Adjustment in the manuscript: 
(cf. discussion, page11, line316): “And this effect was not found in a formal group 
 time  valence interaction. However, testing this was not the aim of our paper 
because we focused on changes over time within depressed patients.” 
 
2.4 Discussion 
 Fifth paragraph: When you discuss structural alterations of the hippocampus, which 
are associated with patients' course of illness, please consider the arbitrary selection 
of clinical variables to characterize patients' course of illness as one source of the 
heterogeneous results (e.g., McKinnon et al., 2009; Zaremba et al., 2018). 
 
Reply to 2.4: We added the related findings in the discussion, which now reads (cf. 
Discussion, page11, line302): 
“Previous cross-sectional and longitudinal studies suggested that hippocampal 
volume is negatively related to duration of illness in MDD, represented by history of 
psychiatric hospitalization (Zaremba et al 2018), number of episodes (MacQueen 
et al 2003, Treadway et al 2015) and duration of untreated illness (Sheline et al 1999), 
though not consistently (Bremner et al 2000, McKinnon et al 2009). At the same time, 
volumetric changes in the hippocampus have been linked to symptomatic 
improvement following treatment (Arnone et al 2012a), suggesting state-dependency 
of hippocampal volume. In the present study, though patients differed in course 
trajectory of depression, changes of brain activation were not related to time spent 
with depression, indicating that functional longitudinal changes observed in the 
hippocampus are load-independent. However, the variety in selected clinical 





Reviewer #3: This study by Ai et al. presents longitudinal fMRI findings in a cohort of 
39 MDD and 28 HC subjects scanned twice over a two-year period using an 
emotional word-encoding and recognition task. Their aim was to identify changes in 
BOLD activation to emotional word encoding in the hippocampus/amygdala that were 
associated with symptom change and with time spent with depressive symptoms 
between measurements. They found a significant inverse association between BOLD 
activation change in L hippocampus (but not R) and symptom change - particularly 
during positive encoding. There was no association between BOLD activation and 
time spent depressed. 
 
There are strengths to this study including a relatively large sample of depressed 
patients scanned twice over a two-year period, which is not an easy feat. The use of 
an emotional word encoding task is not particularly novel, but does build on a 
substantive literature of emotional bias abnormalities in depression. However, there 
are also some downsides including the inclusion of MDD patients with SAD, PD, or 
GAD and concomitant SSRI use and the naturalistic design of the study, which 
precludes the examination of treatment-specific effects on the imaging markers. 
Nonetheless, the study has merit and provides worthwhile findings that build on the 
existing literature in this area. 
 
The study overall is methodologically sound, but I have one comment on the reporting 
of the study sample. In the bottom paragraph of p. 5, it is unclear why only 39 MDD 
participants were included in the final analysis when 64 MDD patients had scan data 
at both time points. This is not well supported in the text. Looking at Fig S1, there are 
several reasons provided for exclusion of these subjects that are poorly described. 
For example, why were 17 subjects excluded for not being symptomatic at S1? If they 
were not symptomatic at S1 then why were they included in the MDD group to begin 
with? Similarly, why was a subject excluded for having a MADRS score that was too 
high at S1? Why was a subject who was "too old" at S1 scanned at all? There needs 
to be more specifics overall for the rationale for exclusion of such a substantial 
fraction of your original sample at S1. 
 
Reply to Reviewer 3: We thank the reviewer for his/her compliments and apologize if 
our description of our sample selection was unclear. Overall, 301 participants in the 
Netherlands Study of Depression and Anxiety (NESDA) were included in the MRI 
sub-study. Of these, as described in the baseline study by van Tol et al. (2010), 225 
participants had valid behavioral and imaging data on emotional words encoding and 
recognition task, which constituted the baseline sample at S1. For this specific study, 
we included MDD patients who met the following criteria: diagnosis of major 
depressive disorder in the past half-year according to the Composite International 
Diagnostic Interview (CIDI life time - version 2) as assessed during the baseline 
interview and a current depressive state at the day of scanning (which on average 
took place 8 weeks following the interview) defined as a score larger than 10 on the 
Montgomery–Åsberg Depression Rating Scale (MADRS). Therefore, 17 patients were 
excluded because they met criteria for MDD during the past half year during the initial 
interview but were not in a depressive state at the moment of scanning. One 
participant with too high MADRS scores at S1 was excluded in order to match the 
participants at depression severity at baseline. One additional participant was 
excluded because its depression severity score increased 146% from S1 to S2, which 
therefore constituted an outlier of clinical worsening. Finally, we excluded one patient 
in low-improved group to obtain a good match on all demographic variables between 
patients and healthy control groups. We now updated the flow chart and its 
descriptions to make the selection clearer. 
 
Adjustment in the manuscript: 
(cf. supplemental figure S1, Figure legend): Flow chart of recruitment and sample 
selection of participants. At baseline measurement (S1), 117 MDD patients and 52 
healthy controls had valid scans during emotional words encoding task. From 
53 of these patients and 13 of healthy controls the second measurement data 
(S2) could not be included because of loss to follow-up or missing behavioral 
data. Moreover, at S1 25 patients were not depressed at time of scanning 
(MADRS 10), one patients with too high MADRS score and 11 healthy controls 
were excluded to obtain a good match with the included patients. One patient 
was excluded based on the relative change of depressive symptom exceeded 3 
standard deviation. In total, 21 symptom-improved patients, 19 non-improved 
patients and 29 healthy controls were included in the final analysis.  
  
 
